HWA
ADAP

Heritage Wealth Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Heritage Wealth Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,333
Closed -$12K – 528
2021
Q4 		$12K Hold
3,333
– – ﹤0.01% 434
2021
Q3 		$17.2K Hold
3,333
– – ﹤0.01% 414
2021
Q2 		$14.2K Hold
3,333
– – ﹤0.01% 432
2021
Q1 		$17.7K Hold
3,333
– – ﹤0.01% 429
2020
Q4 		$18K Buy
+3,333
New +$18.1K ﹤0.01% 415

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Heritage Wealth Advisors's ADAP Position: Q1 2022 in Review

Heritage Wealth Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2022, closing a stake of 3,333 shares — an estimated $12K sold.

Heritage Wealth Advisors first reported a position in ADAP in Q4 2020 and held it in 5 quarters. The position peaked at $18K in Q4 2020. 80 funds tracked by Wall St. Rank hold ADAP as of Q1 2022.

  • Heritage Wealth Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Heritage Wealth Advisors sold 3,333 Adaptimmune Therapeutics shares in Q1 2022, an estimated $12K.
  • Heritage Wealth Advisors first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 5 quarters.
  • Heritage Wealth Advisors's Adaptimmune Therapeutics position peaked at $18K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2022.

Based on Heritage Wealth Advisors's 13F filing for Q1 2022, filed 11 May 2022.